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Abstract. The purpose of this study is to determine the effect of giving temulawak  (Curcuma Xanthorrhiza Roxb) in 
athletes after having running  activity 5000 meters toward hemoglobin, erythrocyte and hematocri  level. The research 
design is double blind randomized controlled trial. The subjects were 35 male football  athletes from PPLP (Centre for 
Education and Training Student) Salatiga, Central Java. The subjects were divided into 5 group with different treatments;  
group I giving temulawak extract capsule containing curcumin (ETKK) 250 mg / day, group II ETKK 500 mg / day, 
group III ETKK750 mg / day, group IV were given multivitamin and mineral (MVM) capsules per day (beta carotene 
5000 UI, Vitamin E 200 UI, Vitamin C 500 mg, 15 mg zinc, selenium 50 mcg) and group V were given placebo while 
the capsule were given for 21 days. The giving of temulawak extract (Curcuma xanthorrhiza Roxb) gave no effect on the 
improvement of hemoglobin levels, eritrsit and hematocrit in athletes after having 5000 meters running test. 
INTRODUCTION 
The improvement of the use of oxygen, especially on performed by contraction muscle, causes the improvement 
of electron leakage of mitochondria that will become ROS (Reactive Oxygen Species) (Clarkson 2000; Sauza 2005). 
Generally, 2-5% of oxygen used in metabolism process is changed into superoxide ion, so that a heavy physical 
exercise is able to cause the improvement of free radical production (Chevion 2003). Oxidative stress caused by 
heavy physical exercise induces erythrocyte damage and reduction of hemoglobin level (Senturk dkk. 2001). The 
damage of erythrocyte effects on age of erythrocytes, in which the age of erythrocytes is normally 120 days. So if 
the production of hydrogen peroxide still continues, it causes anemia because of the damage of erythrocytes. 
Anemia results the lack of oxygen transportation to cell. It gives effect to metabolism of cell, therefore the cell is not 
able to make any regeneration (Guyton; 2002). The function of erythrocyte is as oxygen carrier that carries the 
oxygen through all body’s tissue. Haemoglobin, that binds the oxygen, is the inside part of erythrocyte. 
Haemoglobin carries the oxygen from the lung, and then the oxygen is released when the erythrocyte passes the 
capillaries.   
In normal condition, the form of free radicals is balanced with the form of endogenous antioxidants. Body has 
protection mechanism that neutralize the free radicals by producing endogenous antioxidants, such as SOD 
(superoxide dismutase), GPx (glutation peroxide), and catalase. Body is not able to produce antioxidants, so that the 
body needs exogenous antioxidants from outside of the body. Exogenous antioxidants include vitamin E, vitamin A, 
vitamin C, Cu, ZN, Mn (Gordong 1994; Simajuntak 2007; Winarsi 2011). 
Temulawak (Curcuma xanthorrica roxb) is one of medicinal plants that contains with efficacious active 
ingredients as antioxidants. The study result shows that bioactive subtances contained in temulawak rhizome include 
kurkumin (Kunchandy and Rao 1990 ; Tonnesen and Greenhill1992), demetoksikurkumin and 
bisdemetoksikurkumin (Tonnesen and Greenhill 1992). Another study indicates that active ingredients of 
kurkuminoid found in temulawak has higher antioxidants effectivity than kurkumin, demetoksikurkumin and 
bisdemetoksikurkumin (Sutrisno dkk. 2008). The purpose of this research is to study the effect of giving temulawak 
(Curcuma Xanthorrhiza Roxb) in athletes after having 5000 meters-running activity toward the level of hemoglobin, 
erythrocyte and hematocrit. 
206 
 
METHOD 
The research design used was double blind randomized controlled trial. The subjects were 35 male football 
athletes from PPLP (Centre for Education and Training Student) Salatiga, Central Java. The subjects were divided 
into 5 groups with different treatments; group I was given temulawak extract capsule containing curcumin (ETKK) 
250 mg / day, group II was given ETKK 500 mg / day, group III was given ETKK750 mg / day, group IV was given 
multivitamin and mineral (MVM) capsules per day (beta carotene 5000 UI, Vitamin E 200 UI, Vitamin C 500 mg, 
15 mg zinc, selenium 50 mcg) and group V was given placebo while the capsule were given for 21 days. The giving 
of temulawak extract (Curcuma xanthorrhiza Roxb) gives no effect on the improvement of hemoglobin levels, 
eritrsit and hematocrit in athletes after having 5000 meters running test. The research was conducted in Pusat 
Pendidikan dan Latihan Pelajar Olahraga (Centre for Students Education and Training) Salatiga Central Java. The 
intervention of temulawak extract capsule was given for 21 (twenty one) days. Physical activity was tested with 
5000-metres of fast running. This research has been approved by ethical clearance approval issued by Health Ethics 
Committee Faculty of Medical Diponegoro University Semarang No. 214/EC/FK/RSDK/2012. 
RESULT 
Haemoglobin (Hb), Hematocrit (Ht) and Erythrocyte 
Generally, after the intervention, the mean of haemoglobin level reduces as 0,13±0,69 g/dL (1,2-1,8 g/dL). The 
mean of haemoglobin level on treatment group with ETKK 250 mg and 750 mg increases as 0,16±0,56 g/dL and 
0,10±1,00 g/dL respectively. The reduction of the average of haemoglobin level found on treatment groups with  
MVM 250 mg, ETKK 500 mg and placebo are 0,58±0,73 g/dL, 0,51±0,58 g/dL, 0,34±0,36 g/dL respectively. The 
result of anova test of those groups are not significantly different (p>0,05).    
After the intervention, the treatment group that have the reduction of the average of hematocrit level are group of 
placebo, group of MVM 500 mg and ETKK 500 mg as 1,23±1,30%, 1,23±1,30% and 0,11±5,06% of each. The 
treatment group with  TKK 750 mg and treatment group ETKK 250 mg have the increase of the average of 
hematocrit level as much as 0,74±3,17% and  0,39±1,85% respectively. After performing the anova test, there is no 
significant difference on those five of treatment groups (p>0,05). 
The average number of erythrocytes found is decline after the intervention as 0,06±0,24 million u/L (0,44-0,65 
million u/L). The average number of erythrocytes that have increased is only found on the treatment  group with 
ETKK 750 mg as much as 0,05±0,38 million u/L. The reductions of the average number of erythrocytes of the 
treatment group with ETKK 500 mg, placebo, MVM and ETKK 200 mg are 0,16±0,23 million u/L, 0,09±0,19 
million u/L, 0,07±0,21 million u/L, 0,01±0,16 million u/L respectively. The result of anova test of those groups are 
not significantly different (p>0,05). 
 
TABLE 1. The mean of Haemoglobin, Hematocrit, Erythrocyte Level Based on The Treatment Group Before and After 
Intervention 
Haemoglobin Level  (g/dL)  Placebo ETKK250 mg 
 
ETKK500 mg 
 
ETKK750 mg 
 
MVM p 
Before 13,99±1,01 15,36±0,83 14,86±0,84 14,29±0,91 14,24±0,74 0,045 
After 13,64±0,84 15,51±0,72 14,34±0,63 14,39±1,35 14,19±0,99 0,015 
Difference -0,34±0,36 0,16±0,56 -0,51±0,58 0,10±1,00 -0,58±0,73 0,302 
Hematocrit Level   (%)        
Before 43,21±2,85 46,17±2,53 44,71±2,06 43,91±1,68 44,43±0,70 0,133 
After 41,98±2,61 46,57±2,12 44,60±4,73 44,66±3,29 43,76±2,05 0,123 
Difference  -1,23±1,30 0,39±1,85 -0,11±5,06 0,74±3,17 -0,67±1,64 0,729 
Number of Erythrocyite  
(million u/L) 
      
Before 5,21±0,56 5,25±0,32 5,11±0,32 5,30±0,46 5,46±0,59 0,708 
After 5,13±0,53 5,24±0,29 4,94±0,19 5,34±0,45 5,39±0,53 0,300 
Difference  -0,09±0,19 -0,01±0,16 -0,16±0,23 0,05±0,38 -0,07±0,21 0,580 
 
There is no alteration of the proportion of haemoglobin level before and after intervention on all group of 
treatment. After performing intervention, the proportion of haemoglobin level which experience anemia on group of 
MVM treatment and group of placebo are one athlete (14,3%) of each group. The result of fisher’s exact test shows 
that there is no difference of the proportion of haemoglobin level on all group of treatment (p>0,05). 
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When the proportion of hematocrit level is compared to the hematocrit level before conducting intervention, its 
proportion is slightly difference on the group with MVM treatment. Before intervention, there is 1 (one) athlete 
(14,3%), however no athlete is found after the intervention. The result of fisher’s exact test indicates that there is no 
different of the number of erythrocytes on all groups with treatment (p>0,05). 
 
TABLE 2. Classification of Haemoglobin Level Based on The Group of Treatment Before and After The Intervention. 
Haemoglobin Level  Plascbo ETKK 250 mg ETKK 500 mg ETKK750 mg MVM  p 
n % n % n % n % n %  
Before           1,00 
Anemia  1 14,3 0 0 0 0 0 0 1 14,3  
Normal  6 85,7 7 100 7 100 7 100 6 85,7  
After            1,00 
Anemia  1 14,3 0 0 0 0 0 0 1 14,3  
Normal  6 85,7 7 100 7 100 7 100 6 85,7  
Hematocrit Level            
Before           1,00 
Low  1 14,3 0 0 0 0 0 0 1 14,3  
Normal  6 85,7 6 85,7 7 100 7 100 6 85,7  
High 0 0 1 14,3 0 0 0 0 0 0  
After            1,00 
Low  1 14,3 0 0 0 0 0 0 0 0  
Normal  6 85,7 6 85,7 6 85,7 6 100 7 100  
High 0 0 1 14,3 1 14,3 1 14,3 0 0  
Number of Erythrocyite             
Before           1,00 
Low  1 14,3 0 0 0 0 0 0 0 0  
Normal  5 71,4 6 85,7 6 85,7 5 71,4 6 85,7  
High 1 14,3 1 14,3 1 14,3 2 28,6 1 14,3  
After           0,948 
Low  1 14,3 0 0 0 0 0 0 0 0  
Normal  5 71,4 6 85,7 7 100 6 85,7 6 85,7  
High 1 14,3 1 14,3 0 0 1 14,3 1 14,3  
 
Mean Corpuscular Volume(MCV), Mean Corpuscular Hemoglobin(MCH),  
Mean Corpuscular Hemoglobin Concentration(MCHC) 
After the intervention, the treatment groups  have the reduction of average value of MCV on MVM and placebo 
as 0,33±0,25 fL and 0,06±0,74 fL of each of them. The highest improvement of the MCV value as 0,43±0,56 fL is 
found on the group of 750 mg ETKK treatment. The result of anova test tells that there is no distinction on average 
difference of MCV value on those five of treatment groups (p>0,05). The average value of MCH has decreased after 
the intervention on the group with ETKK 500 mg treatment, the group of ETKK 750 mg treatment and the group of 
MVM treatment as 1,00±0,29 pg/sel, 0,10±0,35 pg/sel  dan 0,09±0,16 pg/sel. The highest improvement as much as 
0,06±0,30 pg/sel is found on the treatment group with ETKK 250 mg. The anova test indicates that there is no 
distinction on average difference of MCV value on those five of treatment groups (p>0,05). The difference average 
of MCHC value has decreased by 0,03±0,36 g/dL (0,90-0,80 g/dL). The average value of MCHC has reduced by 
0,29±0,38 g/dL dan 0,07±0,45 g/dL respectively on the group with ETKK 750 mg treatment and the group with 
ETKK 500 mg treatment. The increase of the average value of MCHC on the group of  ETKK 250 mg treatment, 
placebo, and MVM severally are 0,13±0,40 g/dL, 0,06±0,24 g/dL, and 0,03±0,21 g/dL. The result of anova test 
points that there is no distinction on average difference of MCHC value on those five of treatment groups (p>0,05). 
 
TABLE 3. The Average Value of MCV, MCH, MCHC Based on The Treatment Group Before and After The Intervention 
MCV Value  (fL) Placebo 
 
ETKK250 mg 
 
ETKK500 mg 
 
ETKK750 mg 
 
MVM 
 
p 
Before 83,43±6,34 88,04±3,52 87,63±2,85 83,30±5,71 82,11±8,29 0,206 
After 83,37±5,80 88,04±3,75 87,63±2,96 83,73±5,92 81,79±8,14 0,175 
Difference  -0,06±0,74 0,00±0,84 0,00±0,46 0,43±0,56 -0,33±0,25 0,255 
208 
 
MCHC Value (g/dL)       
Before 26,99±2,24 29,30±1,23 29,13±1,28 27,09±2,23 26,66±3,42 0,084 
After 26,99±2,19 29,36±1,37 29,03±1,09 26,99±2,14 26,57±3,37 0,064 
Difference 0,00±0,28 0,06±0,30 -1,00±0,29 -0,10±0,35 -0,09±0,16 0,776 
Value MCHC (g/dL)       
Before 32,36±0,60 33,26±0,38 33,20±0,59 32,50±0,96 32,37±1,18 0,087 
After 32,41±0,69 33,39±0,67 33,13±0,49 32,21±0,70 32,40±1,21 0,034 
Difference  0,06±0,24 0,13±0,40 -0,07±0,45 -0,29±0,38 0,03±0,21 0,236 
 
Based on the limitation of normal MCV value as 80 – 100  fL, normal MCH value is 28– 34 pg/ sel and normal 
MCHC value is 32 – 36 g/dL  (Kemenkes 2011), the proportion description of MCV, MCH and MCHC category 
accordingly can be seen on Table 4.  
 
TABLE 4. Classification of MCV, MCH, MCHC Value Based on The Treatment Group Before and After the Intervention. 
Classification of MCV Value Placebo ETKK 250 mg ETKK 500 mg ETKK750 mg MVM  p 
n % n % n % n % n %  
Before           0,771 
Microcytic 1 14,3 0 0 0 0 2 28,6 1 14,3  
Normositik   6 85,7 7 100 7 100 5 71,4 6 85,7  
After           0,771 
Microcytic 1 14,3 0 0 0 0 2 28,6 1 14,3  
Normositik  6 85,7 7 100 7 100 5 71,4 6 85,7  
Classification of MCH Value            
Before           0,170 
Hipokromik  4 57,1 1 14,3 1 14,3 4 57,1 4 57,1  
Normokromik  3 42,9 6 85,7 6 85,7 3 42,9 3 42,9  
After           0,143 
Hipokromik   5 71,4 2 28,6 1 14,3 4 57,1 5 71,4  
Normokromik  2 28,6 5 71,4 6 85,7 3 42,9 2 28,6  
Classification of MCHC 
Value 
           
Before           0,297 
Low 4 57,1 1 14,3 1 14,3 4 57,1 4 57,1  
Normal 3 42,9 6 85,7 6 85,7 3 42,9 3 42,9  
After           0,240 
Low 2 28,6 0 0 0 0 3 42,9 1 14,3  
Normal  5 71,4 7 100 7 100 4 57,1 6 85,7  
 
After performing the intervention, there is no alteration on the proportion of MCV. The fisher’s exact test 
indicates that there is no significant difference on MCV proportion of those treatment groups before and after the 
intervention (p>0,05). There is prevalence hipokromik as much as 4 (four) athletes (42,9%) found in each treatment 
group of placebo, ETKK 750 mg and MVM; while, the MCHC value proportion in low category on the treatment 
groups of  ETKK 250 mg and ETKK 500 mg are 14,3% of each of them. The fisher’s exact test shows that there is 
no significant difference on MCV proportion of those treatment groups before and after the intervention (p>0,05). 
The value of MCHC in low category is not found on the treatment groups of ETKK 250 mg and ETKK 500 mg; 
hovewer the result of fisher’s exact test indicates that there is no difference on MCV proportion of those treatment 
groups before and after the intervention (p>0,05). 
DISCUSSION 
Haemoglobin (Hb) 
The average level of haemoglobin found in the treatment groups of ETKK 250 mg and 750 mg increases 
severally as 0,16±0,56 g/dL and 0,10±1,00 g/dL. In line with the research conducted by Sutamik (2007) that tells 
that the give of temulawak extract (Curcuma xanthorrhiza Roxb.) is able to improve the level of haemoglobin on the 
blood of female strain wistar rats (Rattus norvegicus) that be given with lead nitrate solution (Pb(NO3)2). The 
research performed by Sugiharto shows that the give of temulawak rhizome infusion together with the give of 
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solution lead [(PbNO3)2] is able to prevent the reduction of Haemoglobin level of the rats. Nevertheless, the 
treatment groups of MVM, ETKK 500 mg and placebo have had the reduction of the average level of haemoglobin 
(Δ level of haemoglobin) as much as 0,58±0,73 g/dL, 0,51±0,58 g/dL, 0,34±0,36 g/dL respectively. The average 
level of haemoglobin before the intervention is 10,70±0,48 g/dl and the average level of  haemoglobin after the 
intervention is 9,40 ±0,67 g/dl.  
 
Hematocrit (Ht) 
After the intervention, the treatment groups that have had the reduction of average level of hematocrit are 
placebo, MVM and ETKK 500 mg as much as 1,23±1,30%, 1,23±1,30% and 0,11±5,06%. The research performed 
by Bahri dkk. (2012) toward the athletics athletes after running for an hour shows the reduction of hematocrit level 
either on the control or treatment groups (coconut water, sugar and supplement). 
The treatment groups with ETKK 750 mg and ETKK 250 mg have the improvement of average level of 
hematocrit as 0,74±3,17% and 0,39±1,85%. The research performed by Senturk dkk (2004) that involved the 
trained-male students and untrained-male students of Akdeniz University, Antalya, Turki indicates that there is an 
improvement of level of hematocrit on both trained-male students and untrained-male students after having maximal 
physical exercise and giving Vitamin A (β-carotene 50 mg/day), vitamin C (ascorbic acid 1000 mg/day), and 
vitamin E (α-tocopherol 800 mg/day). Sugiarto research (2003) shows that the give of 20% temulawak rhizome 
infusion is able to improve hematocrit level on rats (Rattus norvegicus) after being given the solution of inorganic 
lead.    
 
Erythrocyte 
The average amount of erythrocytes is increase only on the treatment group with ETKK 750 mg as much as 
0,05±0,38 million u/L. The research done by Sugiharto (2004) that gave 20% temulawak rhizome infusion and 0,5 
ml (PbNO3)2) 50 ppm shows that a slight improvement of average amount of erythrocytes as 4,65 ± 0,14 million u/L 
compares to the group of control as 4,60 ± 0,13 million u/L. However, the give of 20% temulawak rhizome infusion 
and 0,5 ml (PbNO3)2) 50 ppm have the improvement of average amount of erythrocytes as 4,65 ± 0,14 million u/L 
compares to the group of control as 4,60 ± 0,13 million u/L. Djojosoewarno and Sjarief research (2002) tells that 
there is an improvement of  of average amount of erythrocytes from 5,65 million u/L to 7,93 million u/L after 
having physical activity on the administration male employees.   
The treatment groups with ETKK 500 mg, placebo, MVM and ETKK 250 mg have the decrease of average 
amount of erythrocytes respectively are 0,16±0,23 million u/L, 0,09±0,19 million u/L, 0,07±0,21 million u/L, 
0,01±0,16 million u/L. In line with the research conducted by Silitonga (2011) indicates that there is the decrease of 
the amount of erythrocytes on the rats (Rattus norvegicus) that have been given the maximal physical activity and 
given daun bangun-bangun for 30 days compare to group of control.  
 
Mean Corpuscular Volume (MCV), Mean Corpuscular Haemoglobin (MCH),  
Mean Corpuscular Hemoglobin Concentration (MCHC) 
After the intervention, the treatment groups that have the reduction of average value of MCV are MVM and 
placebo as much as 0,33±0,25 fL and 0,06±0,74 fL. Dallak (2012) performed the research that finds that there is the 
reduction of average value of MCV on male-Wistar rats after the intervention with vitamin E and vitamin C and 
been swam compares to the control group. The research done by Hossein and Monireh (2012) on the male-
basketball athletes also indicates the decrease of average value of MCV from 91,17 ± 1,94 fL to 91,10 ± 1,92 fL  
after having the intervention of plyometric exercise program. Hovewer, the treatment group with ETKK 750 mg has 
the highest improvement of average value of MCV as 0,43±0,56 fL. Wen et al (2007) shows that there is an 
improvement of average value of MCV from 90,00 ± 4,36 fL to 90,05 ± 5,18 fL on the basketball athletes after 
having the intervention by consuming purple sweet potato leaves (Ipomoea batatas (L) Lam).While, the research 
done by Vilela et al (2010) tells that there is a slight improvement of average value of MCV from 86,25 ± 0,35 fL to 
86,29 ± 0,35 fL on the volunteers after the intervention with the extract of pequi fruit (Caryocar brasilliense Camb). 
 Based on the classification of MCV, there are micrositik category (<80 fL) and normositik category (80-
100 fL) found on all treatment groups. The highest micrositik category is found on the treatment group with ETKK 
750 mg as 2 athletes (28,6%). There is no athlete found in the treatment groups with ETKK 250 mg and ETKK 500 
mg. The proportion of MCV does not change after getting the intervention. The anova test result indicates that there 
is no different on the difference of MCV value on those five of treatment groups (p>0,05). It is not similar with the 
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result of Tanuja research (2011) that be conducted by giving the turmeric extract (Curcuma Longa) and 5 Gy of 
Gamma radiation to Swiss albino mice. This intervention gives the effect to MCV value. 
CONCLUSION 
The give of temulawak extract (Curcuma xanthorrhiza Roxb) does not give any effect to the improvement the 
level of haemoglobin, erythrocytes and hematocrit in athletes after having 5000 meters running test. 
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